We made use of our Nicd/Akt model (detailed above) and a second genetic model, where the expression of mutant KrasG12D and genetic deletion of Trp53 with CRISPR‐Cas9 in vivo (gTrp53) results in KrasG12D‐driven cholangiocarcinoma.30 Here, AKT1 is linked to cholangiocarcinoma.